Theravance Biopharma enters consulting agreement with departing SVP; equity awards to vest

Theravance Biopharma, Inc.

Vijay Sabesan, SVP Technical Operations, left effective Nov 30, 2021 as previously reported.
On Nov 30, 2021, Company and Sabesan entered a consulting agreement to facilitate transition.
Certain outstanding equity awards will vest under the consulting agreement; no dollar amount disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Vijay Sabesan

Other Named Officer

TBPH · Theravance Biopharma, Inc.

Filed: December 6, 2021, 6:59 PM ET

On November 30, 2021, the Company and Mr. Sabesan entered into a consulting agreement to facilitate the transition of activities following Mr. Sabesan’s departure, pursuant to which certain outstanding equity awards will vest.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.6

Vijay Sabesan departed as other_named_officer at Theravance Biopharma, Inc..

Action: departed

Exact text from the filing

On November 30, 2021, the Company and Mr. Sabesan entered into a consulting agreement to facilitate the transition of activities following Mr. Sabesan’s departure, pursuant to which certain outstanding equity awards will vest.

View on SEC.gov

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-146806

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.